Boston Scientific said on Thursday it will buy medtech firm Penumbra in a deal valued at about $14.5 billion to expand its ...

Heart failure symptoms have been reversed in patients with a new pacemaker that changes how the heart is fuelled.

The French clinical stage company focused on cardiac innovation received the funds from a Series C funding round and the EC’s ...

Atrial fibrillation is one of the most common kinds of arrhythmia, causing the heart not to contract properly in order to ...

Boston Scientific is purchasing heart-device company Penumbra for roughly $14.5 billion in cash and stock, marking the ...

Supraglottic airway (SGA) devices used for out-of-hospital cardiac arrest (OHCA) were more successful at first attempt, but ...

This morning Murj, developer of a digital data collection platform for implantable cardiac devices, announced that it raked in $8.5 million in a series B financing led by Longitude Capital, with ...

Heart failure affects 6.5 million people in the U.S., with an additional 550,000 newly diagnosed each year. Heart failure hospitalizations are a leading cause of admissions for those 65 and older, ...

A new survey finds nearly two‑thirds of Americans use smartwatches or other devices to track heart health, but only 1 in 4 ...

CINCINNATI, Ohio — Children and adolescents with pacemakers and implantable cardiac defibrillators (ICDs)--and their parents--suffer from a poorer quality of life than both healthy children and ...

Deactivation of implanted cardiac devices in terminally ill patients is common. The practices and attitudes associated with pacemaker deactivation differ significantly from those associated with ICD ...

The clinic will be able to accommodate 1,500 patients over a long period and 50 patients with a left ventricular assist ...